MT Group values the continued partnership with our customers. Our commitment has been and always will be to support researchers with the highest quality biospecimen-focused CRO services. Our goal has been and always will be to support researchers with the highest quality biospecimen-focused CRO services. We look forward to exploring new collaboration opportunities with you.
New Capabilities
We continue to expand our site network, broadening our reach in the following areas:
* Cardiological diseases: hypertension, myocardial infarction, and hypercholesterolemia
* Autoimmune diseases: inflammatory bowel disease, diabetes, lupus, and rheumatoid arthritis
* Dermatological disorders: atopic dermatitis and psoriasis
* Pulmonary diseases: asthma, chronic obstructive pulmonary disorder, and pulmonary hypertension
* Gastrointestinal diseases: NASH, irritable bowel syndrome, gastritis, Barrett’s esophagus, and gastric ulcers
* Infectious diseases: hepatitis, influenza, and COVID-19
* Latin America, Europe, and Asia
* Large academic centers and biobanks
Select Studies
MT Group has conducted hundreds of biospecimen studies across diverse therapeutic areas, including:
* 2,000 subject multi-cancer with matched controls
* NASH biopsy tissue and blood
* High risk / pre-cancer subjects collected at colonoscopy, mammogram, and CT scan
* Healthy Asian-Americans and African-Americans with a full medical assessment prior to blood draw
* Fresh lung cancer blood collected on-therapy and post-therapy
* Post neoadjuvant IO and chemo resection tissue
* Fresh skin and blood from healthy subjects and those with dermatological autoimmune diseases
* Subjects collected post-COVID infection, influenza infection, and immunization
MT Group thanks you for your continued partnership. We look forward to supporting your research needs.
Email Us
"*" indicates required fields
